Compare Mesoblast Limited (MESO) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Snap On Incorporated — how do they compare? Mesoblast Limited trades at $16.23 (market cap $2.17B), while Snap On Incorporated trades at $407.13 (market cap $21.06B). The key difference: Snap On Incorporated is far larger — about 9.7× Mesoblast Limited's market cap, and Snap On Incorporated pays a 2.4% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SNA | |
|---|---|---|
Market Cap | $2.17B | $21.06B |
Sector | Technology | Technology |
52-Week High | $20.96 | $414.97 |
52-Week Low | $12.88 | $317.79 |
Enterprise Value | $2.17B | $20.58B |
Dividend Yield | — | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Snap-on Incorporated (SNA) trades at $406.53, down 1.09% on the day, near the consensus price target of $407.50. The stock shows a bullish technical trend with strong moving average signals and support at $403. Fundamentally, SNA maintains robust profitability with a 19.6% net income margin and 17.83% ROE, though Q1 2026 EPS slightly missed expectations. Recent acquisitions like Diesel Laptops for $100 million highlight strategic growth initiatives.
Outlook remains positive with 65% analyst buy ratings and a dividend yield supported by consistent cash flow. Key risks include margin pressures and muted revenue growth. The upcoming Q2 2026 earnings report on July 23, 2026, will be critical for validating current valuation multiples amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
